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Abstract
Due to the relatively limited amount of work done to date on developing prosthetic vein (as
opposed to cardiac) valves, advances in this topic require progress in three distinct areas: 1)
improved device design, 2) relevant device testing conditions, and, 3) appropriate parameters for
evaluation of results. It is the purpose of this paper to address two of these issues (#2 and #3) by:
1) performing a study of normal volunteers to quantify the anatomy and hemodynamic features of
healthy venous valves, 2) construction of a 2-step, in vitro testing procedure, which simulates both
physiologic and postural conditions seen in the lower extremity venous system, and, 3) defining
several modified and new parameters which quantify dynamic valve characteristics.
Background
Although over 50 designs for prosthetic cardiac valves
have been put forward over the past 40+ years and exten-
sive testing performed on many of these devices resulting
in millions of valves being implanted in patients [1], only
a handful of concepts have been put forward for a pros-
thetic venous valve [2-7] and only 1 or two devices have
reached clinical trials as yet [8]. Simultaneously, it is esti-
mated that between 6–7 million patients suffer from
chronic venous insufficiency [CVI] of the legs with
approximately 900,000 new patients be diagnosed annu-
ally in the United States [9]. Of these, about 1–2% will
develop venous stasis ulcers of the lower extremities with
many of them potentially benefiting from a satisfactory
venous implant.
Thus, there remains a large, unmet demand for a function-
ing prosthetic vein valve, particularly one designed for
implant into the proximal veins. The overall objectives of
this study, then, were to create a prosthetic vein valve
capable of successful clinical implantation which would:
1) provide minimal resistance to antegrade flow, 2) re-
establish prevention of reflux flow, and, 3) remain patent
for a minimum time period. To accomplish this, several
novel designs of a valve frame and leaflet component were
conceived which then required evaluation under relevant
venous conditions. Thus, in vitro testing systems were
developed to provide physiologic conditions under typi-
cal postural positions appropriate for a valve in the com-
mon femoral vein (CFV) position. Measurements were
made of standard dynamic variables and both traditional
and novel parameters were also derived from these data.
Previous related work was done by Hasaniya who used a
rudimentary system to evaluate a vein valve constructed
out of bovine jugular vein [7]. His approach was to simply
place the construct vertically into a closed dynamic flow
system such that the leaflet operation could be observed
under ultrasound imaging. The valve system was "evalu-
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ated continuously at various pressures", including 200–
260 mmHg.
One of the more detailed systems was described by Qui et
al. [10] who evaluated the fluid dynamics of two venous
valve models made from bovine jugular vein valves. The
system had the ability to control the steady forward flow
through a horizontally mounted, 25 mm ID valve test sec-
tion by adjusting the height of a downstream reservoir (up
to 20 cm) relative to that of an upstream reservoir (fixed
at 30 cm). Oscillatory effects were introduced by a third
tank placed downstream and mounted on a rotary wheel
such that it induced an additional backpressure from 0 to
13.5 cm H2O. This feature was designed to simulate respi-
ratory and/or muscle pump actions. Flow was measured
using an EMF, pressure was monitored at a single point
immediately downstream of the valve and a glycerin in
water blood analog fluid was used. Valve opening area
was measured using the electric current generated by a
photo detector that sensed the amount of light intensity
from a He-Ne laser beam expanded to 15 mm diameter
that was able to pass through the valve along its axis. Axial
velocities upstream of the valve, at the valve exit, and 2 cm
downstream of the valve exit were measured with a 4 W
Argon-ion laser Doppler anemometer. This system was
used to test a stented, formaldehyde treated bovine jugu-
lar vein valve and a stentless bovine jugular vein valve
conduit. Their results confirmed the theory that vein
valves are operated by a pressure differential rather than
flow and that no reflux is needed to completely close the
valve. Additionally, it was shown that the vein valve sinus
expands rapidly upon backpressure, which was deemed to
be a critical characteristic to consider when designing
prosthetic venous valves.
A number of other studies have been performed where
compliant tubing was used to contain the valve [11-14].
In particular, Raju et al. [15,16] showed that a collapsible
tube helps to buffer pressure variations in the vein and,
upon closure of the valve, the tube below the valve col-
lapses, producing venous pressure reduction. More
recently, Buescher et al. [17] tested thin-walled latex and
polyurethane film vein valves placed in a 12.7 mm latex
tube which was mounted vertically and exposed to flow
moving in either the antegrade or retrograde directions
(depending upon input/output connections) between an
arterial and a venous reservoir. A fluid medium (either
0.9% saline or 42 wt% glycerin solution) was gradually
drained from the arterial reservoir into the venous reser-
voir over a height variation that produced flow rates from
0 to 15 ml/s. Measurements were made of the mass flow
rate, various pressures including the differential pressure
across the valve, and cross-sectional images from an
arthroscopic camera. The primary output variable ana-
lyzed was the competency, C, which was defined as the
percent ratio of the antegrade minus the retrograde flow
rate divided by the antegrade flow rate to evaluate the
effects of leaflet gap widths and sinus sizes.
Methods
A study was first performed on normal volunteers to
quantify the anatomy and dynamics of healthy venous
valves (The University of Akron Institutional Review
Board, Application #20040140). A total of eleven superfi-
cial (SFV) and common femoral veins (CFV) in eight indi-
viduals were non-invasively examined using a Duplex
ultrasound scanner (Siemens Medical System Incorpo-
rated, Ultrasound Group, Issaquah, WA). Because venous
dynamics are a function of both hydrostatic and transmu-
ral pressures, measurements were taken under a combina-
tion of postural positions and physiologic conditions. For
example, venous pressures significantly increase by: 1)
elevating from a supine to a standing position, 2) induc-
ing gait via the activation of the skeletal muscle pump,
and, 3) breathing through changes in intrathoracic pres-
sure. Thus, measurements were taken under various pos-
tural and dynamic conditions, including supine
breathing, supine ankle flexion, standing breathing, and
standing ankle flexion. Measurements were also taken
during a Valsalva maneuver, which is defined as an
attempt to forcibly exhale while keeping the glottis closed.
This is an extreme condition in which the thoracic vena
cava collapses leading to the application of a high retro-
grade pressure to the most proximal venous valves.
Parameters obtained using B-mode imaging included CFV
diameter, presence or absence of valve sinuses, SFV diam-
eter, leaflet length, and SFV leaflet to wall angle. Peak SFV
augmentation velocity and cycle period were obtained
from the single channel pulse Doppler mode. Other
parameters were derived from the raw data and included:
leaflet to SFV diameter ratio, SFV area, SFV flow rate, SFV
peak Reynolds number, and SFV Womersley number.
Although these data are too extensive to report here, the
average values were used as a guide for designing an in
vitro flow test system and the first generation of proto-
typic, prosthetic valves.
The next step in the development process was to identify
device designs, which minimally satisfied the criteria of 1)
opening upon antegrade flow and 2) closing upon retro-
grade flow. Once conceived, these designs were then mod-
ified by varying several key dimensional parameters in
order to provide a range of configurations that could
result in measurable differences in valve function. [Note:
A detailed description of these devices and their func-
tional outcomes will be presented in a subsequent publi-
cation.] Furthermore, it was decided that a 2-stage testing
process would provide the ability to first observe the
devices in a more global operation (i.e. opening and clos-
ing, breakage, etc.) before proceeding with more rigorousBioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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testing. Thus, two test systems were built, one of which
provided first-cut information about the valve's respon-
siveness to basic flow conditions (forward steady flow and
step reverse flow) and the second of which provided more
realistic physiologic conditions. Because of the rough,
observational nature of the first testing protocol, the
devices and test system were scaled up by a factor of 2:1 in
order to better observe device operation. Those devices
which passed this vertical column Mock-up Steady Flow
System testing were then re-fabricated as 1:1 scale devices
and more thoroughly evaluated in the horizontal Physio-
logic Flow System.
a. 2:1 Mock-Up System
The main purpose of the 2:1 Mock-Up System was to
mimic conditions in the standing position where
demands on the valve were most extreme. Therefore, a
vertical column was constructed in which the candidate
devices were placed (Fig. 1). The outlet of the column was
at a height of 55 cm above the test specimen to simulate
the elevation of the heart above a proximal vein valve in
the standing position. For simplicity, a constant flow
pump (IWAKI PULSA Feeder, Interpace Corporation,
Rochester, NY) was used to provide the driving pressure
and tap water was used as the test fluid. Initially, valve
misalignment within the test section and system leakage
at the valve connection were commonly experienced.
Both of these conditions were corrected through the use of
a threaded adaptor to secure the valve Mock-ups in place.
Matching threading was added to each of the prototype
valves, which could then be screwed into the system after
the application of Teflon® tape. The flow loop was closed
by lowering a one-inch inner diameter Tygon® tube over
the valve and securing it with a clamp. Upstream of the
test section was a reservoir with a submersible pump
(Model 1, Little Giant Pump Company, Oklahoma City,
OK) that filled a constant elevation (20 cm) reservoir
(Tower I) that, in turn, functioned to prime the constant
flow pump. The output of the constant flow pump to the
test section was regulated by a variable resistor placed in a
recycle stream to the reservoir. This allowed the flow rate
delivered to the test section to be set without altering the
pump output.
Upon scaling up to the 2:1 Mock-up system, a balance of
viscous and inertial forces was maintained by matching
the Reynolds numbers of the system to that obtained in
the Normal Volunteer Study:
where Re = characteristic Reynolds number, ρ = the fluid
density, v = the fluid velocity, D = the tubing diameter,
and, μ = the fluid viscosity; NL subscripts denote parame-
ters of the normal volunteer study while MU denotes
those of the Mock-up flow system.
The densities of both systems were assumed to be equal
(ρNL = ρMU) while the diameter of the Mock-up system was
twice that of the average normal volunteer vessel diameter
(DMU = 2.0DNL). Furthermore, the viscosity of blood was
three and a half times greater than the tap water in the
Mock-up system (μNL = 3.5 μMU). These relationships
allowed for the velocity of the Mock-up system to be
determined relative to that of the normal volunteer study:
Next, the value of VMU was applied to the continuity equa-
tion as seen in Equation 3:
where QMU = the volumetric flow rate in the Mock-up test
system (L/min) and AMU = the cross-sectional area of the
test section in the Mock-up system (cm2). This required
that for VNL = 14.2 cm/s and DNL = 1.25 cm that QMU =
0.599 L/min (corresponding to a mean Re = 146).
Testing of a given valve consisted of recording differential
pressure and flow while adjusting the variable resistor in
the recycle stream to obtain the desired flow to the test
section. After the flow rate to the test section stabilized at
the desired value for a few seconds, the pump was turned
off and the flow allowed to recede under the force of grav-
ity. The pump remained off until the level of the water
reached an equilibrium point with the height of the fluid
in Tower I. This protocol was repeated five times for each
valve. Data recordings consisted of analog differential
pressure and flow waveforms. Differential pressure was
measured with a transducer (Model P305D, Validyne
Engineering Corporation, Northridge, CA) whose ports
were connected to the test section at a distance of 27 cm
above and below the test valve to allow for placement of
the device inside a view box. The transducer itself was set
at a height of 23 cm above the reference tubing to match
the elevation of the device. Flow was measured with a 16
mm inner diameter transonic flow probe connected to the
system just proximal to the recycle stream. The signal was
processed by a transonic flow meter (Model T108, Tran-
sonic Systems, Ithaca, NY). Ultrasonic reflectors for the
flow transducer were not needed because of the mineral
particles in the tap water. Both differential pressure and
flow waveforms were relayed to a PC interface system
(WINDAQ™, DATAQ® Instruments Incorporated, Akron,
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OH) for recording and display. The waveforms for the
Mock-up flow system were converted from a voltage sig-
nal to either their corresponding average differential pres-
sure or flow values via linear calibration curves based on
known data points. Through the acquisition system, data
were obtained to the nearest 0.001 V with a temporal res-
olution of 1 ms at a sampling rate of 1000 Hz. Using the
calibration equations, this corresponded to a resolution of
0.0345 mm Hg and 0.00264 L/min for differential pres-
sure and flow rate, respectively.
Measured parameters for the 2:1 Mock-up system
included mean flow rate, average differential pressure,
valve closing time, reflux, and leakage. Each variable was
defined by isolating a specific region in the time domain
based on characteristic features of the differential pressure
and flow waveforms. Mean flow rate and average differen-
tial pressure were time averaged over the period of one
second before the constant flow pump was turned off.
This provided the dynamic conditions that were acting on
the valve as valve closure occurred. The time marker for
the pump shut-off was defined as an initial sharp decrease
in the flow waveform. The pump shut-off time was also
used as the start marker for both the valve closing time
and reflux parameters whereas the end marker was
defined using the first rebound spike of the differential
pressure waveform. Physically, the Valve Closing Time,
VCT, was the time it took for the valve leaflets to first
approximate one another after cessation of the forward
driving pressure source. Correspondingly, Reflux Volume,
, was defined as the volume of fluid that passed retro-
grade through the valve during the closing time period.
The time interval over one second following the end
marker was defined as the "1st Leakage Interval" where the
volume of fluid that leaked distally through the valve was
the leakage. The same thing was done over the next sec-
ond, which was the "2nd Leakage Interval".
The only calculated parameter associated with the 2:1
Mock-up system was valve resistance, R, which was
defined as the ratio of the average differential pressure to
the mean flow rate. This value quantitatively described
how much of a frictional effect the valve had on antegrade
flow.
b. 1:1 Physiologic Flow System
The 1:1 Physiologic Flow System (Fig. 2) was intended to
mimic the more complex conditions observed in the nor-
mal volunteer study. It combined steady and pulsatile
flow components where steady flow was provided by a
constant elevation (20 cm) reservoir (Tower I) and pulsa-
tile flow was provided by a roller pump (Drake-Willock,
Hemodialysis Systems, Oregon), which had been modi-
VR
A schematic of the vertical column 2:1 Mock-Up System Figure 1
A schematic of the vertical column 2:1 Mock-Up System.BioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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fied by the removal of one of the two rollers acting upon
a compliant tube (bicycle inner tube). Cyclic flow output
of the roller pump was superimposed onto the steady
component by placing it in series with the output of
Tower I and operating it at frequencies of 15 and 30 rpms
to simulate ankle flexion and breathing conditions,
respectively. A second constant elevation (55 cm) reser-
voir (Tower II) was also placed downstream of the valve.
The purpose of Tower I was to simulate the residual arte-
rial pressure entering the venous system while the purpose
of Tower II was to simulate the hydrostatic backpressure
induced in the standing position. The test section again
contained a threaded adaptor similar to that of the Mock-
up flow system, which facilitated valve installation and
alignment while simultaneously preventing system leak-
age. The system was filled with a blood analog fluid com-
posed of a mixture of tap water and 3.45% Dextran
(SIGMA Chemical Company, St. Louis, MO). As with the
2:1 Mock-up system, data recordings consisted of analog
differential pressure and flow waveforms with the only
difference being that differential pressure was measured
across ports separated by 31 cm on either side of the test
valve, again to allow for mounting within a view box.
Testing of a given valve was performed by recording differ-
ential pressure and flow over each combination of body
position (Supine or Standing) and dynamic condition
(Breathing or Ankle Flexion) over forty cycles (Table 1).
Procedurally, this was done by adjusting the steady flow
rate to 0.35 L/min (Re = 170) using the variable resistance
valve proximal to the test section while the pulsatile pump
was off and the valve to Tower II closed. With the roller
pump set at 15 rpm, the supine breathing (SUBR) simula-
tion was created. After the first forty cycles, the standing
breathing (STBR) condition was produced by opening the
valve to Tower II. Halfway through the testing protocol,
the roller pump was shut off, the steady flow rate set to
0.75 L/min (Re = 364), the roller pump reset to 30 rpm,
and the valve to Tower II closed resulting in the supine
ankle flexion (SUAF) simulation. Finally, after the 120th
cycle, standing ankle flexion (STAF) was created by open-
ing the valve to Tower II. This protocol was repeated for
each valve. Again, the waveforms for the physiological
flow system were converted from voltage signals to either
their corresponding average differential pressure or flow
values via linear calibration curves with resolutions simi-
lar to those of the 2:1 Mock-up system.
Measured parameters obtained in the supine position
included cycle period, mean flow rate, and average differ-
ential pressure. Valve closed time, reflux volume, and for-
ward volume were the measured parameters for the
simulated standing position. Again, each variable was
defined by isolating a specific region in the time domain
based on characteristic features of the differential pressure
and flow waveforms. Extracting direct parameters of inter-
est from the supine position data consisted of isolating a
single flow cycle and running the statistics function of the
data processing software. Doing so provided cycle period,
mean flow rate, average differential pressure, and root
mean square flow rate. Obtaining measured parameters
from the standing position data was somewhat more
complex in that it required dividing the flow waveform
into two distinct temporal regions per cycle. The first
region was the period in which flow was negative and was
referred to as the "Valve Closed Time." The volume
change during this period was considered the Reflux Vol-
ume,  , while the volume change during the remainder
of the cycle in which flow was positive was considered the
Antegrade Volume,  .
In the supine position, valve closure did not occur for
either physiologic condition because the flow never
reversed. Thus, the calculated parameters for this position
evaluated the valve's influence on forward flow through
the computation of Resistance, R, and Effective Orifice
Area, EOA. Resistance was defined the same way as with
the Mock-up flow system – the ratio of average differential
pressure to mean flow rate and is only appropriate for
describing steady flow systems. On the other hand, EOA
(cm2) is a measure of the valve's orifice area based on a
modified Venturi contraction and is a standard quantita-
tive descriptor used for cardiac valves. It takes into account
all of the losses associated with the valve under pulsatile
flow conditions and is defined as:
where Qrms = the RMS flow rate in cm3/s, Cd = the experi-
mentally determined constant in   and,
 = the average difference between systolic and diastolic
pressures in mmHg.
While there is extensive experience in applying EOA to
cardiac valve testing, it was felt that using the RMS flow
rate and systolic and diastolic pressures was not appropri-
ate for the venous system, particularly since more direct
input measures were available. Thus, mean flow rate and
differential pressure were used along with an empirical
constant that was determined by measuring flow and dif-
ferential pressure in the open tube (i.e. with 'No Device'
in place), which corresponded to a known orifice area.
Thus, the constant, Cd, was solved for using Equation 4 for
both the supine breathing and ankle flexion simulations.
VR
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Since valve closure and reflux only occurred in the simu-
lated standing positions, all calculated parameters regard-
ing reflux were obtained only for STBR  and  STAF
conditions. The first of these was the Percent Reflux,
%Ref, which was defined as the ratio of reflux volume to
forward volume during one cycle so that it would be inde-
pendent of small, yet distinct, deviations in the antegrade
volume. The energy required to re-pump the reflux fluid
through the valve, the Reflux Energy Loss, REL (J), was
defined as:
where F = force (N), d = distance (m), ρ = water density
(kg/m3),   = Reflux volume (m3), g = the gravitational
constant (m/s2), and, A = the cross sectional area of the
test section (m2).
Another term, the Antegrade Energy, AE, was defined sim-
ilar to REL, where AE (J) quantified the energy produced
by the pump in propelling the fluid proximally:
where   = the Antegrade volume (m3).
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A schematic of the horizontal 1:1 Pulsatile Flow System Figure 2
A schematic of the horizontal 1:1 Pulsatile Flow System.BioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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Finally, the REL was compared to the AE to provide the
Energy Retention, η:
Statistical analysis for the Mock-up data consisted of a
one-way analysis of variance (ANOVA) at a significance
level of 0.05 performed on mean flow rate, which was the
controlled variable, and a linear regression was performed
between Valve Closure Time and Reflux. For the physio-
logic data, a series of one-way ANOVA tests were run at a
significance level of 0.05 on the variables that were most
relevant to valve selection. These parameters included
average ΔP, R, EOA, ,  %Ref, REL, and η. The analysis
was performed for both dynamic conditions in which the
respective parameter was measured. When a significant
difference existed, grouping was provided by the SNK pro-
cedure and was performed by a computer program (SAS,
SAS Institute Incorporated, Cary, NC). To determine the
repeatability of the system, one prototype valve was
tested, removed and then re-inserted into the system for
repeat testing. Those results were then evaluated to test for
any statistical differences.
Results
Results of the normal volunteer study were extremely val-
uable in defining both typical dimensions and anatomy
of veins in the proximal lower extremity, but also in quan-
tifying the velocities, flow rates, and cycle periods under
various postural and physiologic conditions. Specifically,
over the 11 subjects, the common femoral vein diameter
was 1.04 ± 0.14 cm and peak flow rates (derived from
peak velocities) were 0.6 L/min, 1.34 L/min, 0.78 L/min
and 1.6 L/min for the cases SUBR, SUAF, STBR and STAF,
respectively. Based on these data, a diameter of 1.25 cm
was chosen for the prosthetic valve design to allow for
some distention of the vein upon insertion. Representa-
tive values for peak flow rate under breathing and ankle
flexion conditions were taken (0.69 L/min and 1.5 L/min,
respectively) as the average values measured in the two
postural positions (Supine and Standing), since the
breathing and ankle flexion movements acted as the pri-
mary driving forces in each case. These peak values were
then obtained in the 1:1 Pulsatile Flow System by setting
the steady flow component to 50% of those values (0.35
L/min and 0.75 L/min, respectively) and allowing the
roller pump to superimpose an additional unsteady com-
ponent. Pumping frequencies were based upon typical
breathing (~15 breaths/min = 15 rpm, or 0.25 Hz) and
walking (~30 steps/limb/min = 30 rpm, or 0.5 Hz) cycles.
To illustrate the overall testing procedure, a preliminary
vein valve design was developed (Fig. 3). This device has
several novel features [18] and was conceived in order to
allow for a normally open device that fully closes upon
application of backpressure. A 2:1 scale device was built
using SLA fabrication techniques and incorporating the
threaded extension as described earlier. The device frame
was then wrapped with a 5 mil (127 μm) thick sheet of
Biospan® (Polymer Technology Group, Berkeley, CA) to
serve as leaflets. These were cut to a shape such that the
closed leaflet edges contacted along a straight line across
the valve lumen.
a. 2:1 Mock-Up System
The prototype device was then installed in the 2:1 Mock-
up system and evaluated as described earlier. Initial obser-
vations showed that the leaflet had a natural tendency to
fold inwardly along a nearly diagonal line between the tip
of the flange and a point halfway between the two flanges
along the base. Additional observations also showed that,
for the leaflets to close quickly and reliably, they needed
to have some initial inward deflection. These two issues
were resolved by modifications to the side of the frames
and means of attachment of the leaflet to the base. A
threaded extension was also added at this point to
improve axial alignment of the device and to reduce leak-
age around connectors (Fig. 4).
A set of these devices was fabricated and a series of tests
were then made on these designs in the 2:1 Mock-up Sys-
tem. Key results for the prototype device were that it had
a forward steady flow pressure drop of 1.25 ± 0.153
mmHg and a resistance of 1.92 ± 0.578 mmHg*min/L.
Under sudden hydrostatic backpressure conditions, the
valve required 1.38 ± 0.0447 s to close and allowed 19.9
± 4.40 cm3 of reflux followed by 4.36 ± 1.48 cm3 and 1.23
± 1.02 cm3 of leakage during the 1st and 2nd one second
post-closure intervals, respectively.
η =− 1
REL
AE
(7)
VR
Table 1: 1:1 Pulsatile Flow System Testing Protocol.
Test Condition Steady Flow rate (L/min) Pulse Frequency (rpm) Hydrostatic Backpressure
SUBR 0.35 15 OFF
SUAF 0.75 30 OFF
STBR 0.35 15 ON
STAF 0.75 30 ONBioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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b. 1:1 Physiologic Flow System
After completion of tests on a series of such devices, 1:1
prototypes were similarly constructed and evaluated in
the pulsatile flow system to see what differences dimen-
sional scale and test conditions would make. Results of
these tests are shown for the 'No Device' case and one
valve prototype under supine and standing conditions in
Tables 2 and 3, respectively. The purpose of the 'No
Device' case was: 1) to quantify losses in the system (i.e.
tubing, connectors, etc.) which were not related to the test
device itself, and, 2) to serve as a baseline for worst case
values that would be seen with a completely incompetent
valve. [Note: For the EOA calculations, values for Cd under
the 'No Device' case were 2.32 ± 0.03 
and 6.38 ± 0.142   for the SUBR  and
SUAF conditions, respectively.] Finally, the results from
repeatability testing of these variables over two runs on
the same prototype valve design under supine and stand-
ing conditions are shown in Tables 4 and 5, respectively.
Discussion
a) 2:1 Mock-Up System
From a procedural standpoint, the Mock-up flow system
proved to be an essential element in the development of
second-generation optimized valve designs. The 2:1 scale
and the steady flow component allowed for detailed
observations to be made over the course of an extended
time period, which would have been much more difficult
to make on the 1:1 Physiologic Flow System alone. Simi-
larly, the vertical column arrangement provided the abil-
ity to study the valve when it was subjected to the most
extreme clinical condition. The Mock-up system was par-
ticularly valuable in providing information about frame-
leaflet interactions and how the leaflet collapsed under a
uniform reversing pressure. These capabilities led to
observations that initiated the incorporation of features
that were essential to the dynamic performance of the
leaflets. Thus, it was concluded that the Mock-up was a
necessary intermediate step in the design and develop-
ment of the optimally designed valves.
Although dynamic similarity was maintained, the data
obtained from the Mock-up flow system were not used to
select the best performing second-generation optimized
design. However, these results were able to indicate that
the test device did have low forward resistance and reason-
ably low reflux. [Note: It was at this point in the design
process that consideration was given to: 1) devise out-
come parameters which were more specific to vein valve
operation, and, 2) include recordings of tests with 'No
Device' installed so that direct comparisons could be
made of the prototype as a measure of relative effective-
ness versus a totally incompetent valve.]
b) 1:1 Physiologic Flow System
The 1:1 Physiologic Flow System was valuable in simulat-
ing four realistic postural and physiologic conditions
cm mmHg s ⋅⋅ −
1
2 1
cm mmHg s ⋅⋅ −
1
2 1
Prototype design of venous valve in the Open (left) and Closed (right) positions consisting of a solid circular base, frame struts  with uniquely shaped flanges, and a flexible leaflet material Figure 3
Prototype design of venous valve in the Open (left) and Closed (right) positions consisting of a solid circular base, frame struts 
with uniquely shaped flanges, and a flexible leaflet material.
Base
Frame Strut 
Flange
Commissure
Leaflet BioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
Page 9 of 12
(page number not for citation purposes)
(SUBR, SUAF, STBR, and STAF) for vein valve testing,
which provided data to evaluate the second-generation,
optimally designed valves. The physiologic system was
relevant to the dynamic conditions of the veins in the leg,
which were necessary for a full evaluation of the different
valves of the second generation, optimized design.
More specifically, by reducing the prosthetic devices to
life-size (i.e. 1:1 scale) models, it was possible to obtain
more realistic results and to confirm whether the devices
would operate as well under physiologic conditions.
However, this scale reduction also magnified some of the
limitations in function of the device such as increased
flow resistance and greater reflux due to decreased ability
of the leaflet material to conform to the strut shapes. The
smaller size also reduced precision of the fabrication proc-
ess and, therefore, increased the relative impact of any
incurred defects. Furthermore, by testing in a pulsatile
flow system, it was possible to evaluate the effects of larger
inertial forces and cyclical flexion on the device. This was
important because opening and closing of the valve is
strongly dependent upon the peak dynamic forces of the
fluid and because of possible deformation or failure
responses of the device after repeated operation. It was
observed that the shorter durations of the opening and
closing phases produced by the oscillatory flow condi-
tions resulted in some designs not being able to close
quickly enough and that the leaflets tended to achieve a
more repeatable mode of operation after several cycles.
Unfortunately, there are virtually no comparable data
from other prosthetic vein valves and it is unrealistic to
compare these values to those of prosthetic cardiac valves
due to large differences in test conditions – i.e. higher
operating pressures (~2×), flow rates (~10×) and shorter,
more abrupt cycles. As mentioned earlier, however, sev-
eral outcome parameters were either modified or devised
during this procedure in order to better quantify certain
important device characteristics. For example, EOA was
included because of its widespread use in evaluating car-
diac valves. However, the standard definition of EOA is
based on input data readily available to clinicians, i.e.
systolic and diastolic pressures and root-mean-square
flow, rather than more direct measures of pressure differ-
ence and flow rate per se. Furthermore, while the reflux
volume is important, the question arose as to "how much
reflux is too much?" Since it was difficult to estimate the
amount of excess volume that the lower limb could toler-
Actual 2:1 scale device with optimized frame and shaped  Biospan® leaflet Figure 4
Actual 2:1 scale device with optimized frame and shaped 
Biospan® leaflet. A threaded extension from the base (not 
shown) screwed into the test section fixture to improve 
alignment and prevent leakage.
Table 2: 1:1 Pulsatile Flow Results for Prototype vs. 'No Device' in Supine Position.
Test Condition Device ΔP (mmHg) R (mmHg*min/L) EOA (cm2)
SUBR None 13.3 ± 0.0272 21.3 ± 0.271 1.23*
Prototype 14.6 ± 0.0012 23.5 ± 0.0338 1.12 ± 0.0166
Change 1.33 2.23 0.11
SUAF None 7.97 ± 0.0935 6.00 ± 0.163 1.23*
Prototype 8.81 ± 0.157 7.37 ± 0.110 1.09 ± 0.0111
Change 1.84 1.37 0.14
* Calculated value based on tube dimensionsBioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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ate over a given period of time, an alternate approach to
this issue was taken by simply looking at the energy 'cost'
of re-pumping the reflux flow. This, then, led to the Reflux
Energy Loss (REL) parameter, which measured the work
needed to lift the reflux volume of fluid against gravity the
equivalent height of one point just distal to one point just
proximal to the valve. Finally, collection of data with 'No
Device' installed proved very useful for making compari-
sons of a given device (regardless of its overall ranking)
against the worst possible case to determine the improve-
ment it provided versus a totally defective valve (i.e. the
clinical equivalent of CVI). These measurements also
helped to establish the full-scale range of a given parame-
ter.
Ultimately, the pulsatile flow system provided all of the
data used for valve selection. In particular, the SUBR and
SUAF conditions allowed for the evaluation of valves in
terms of R and EOA while the STBR and STAF simulations
characterized valves according to  , %Ref, REL, and η.
Both supine simulations were found to produce fairly
realistic conditions but neither induced valve closure. This
was consistent with observations made earlier during the
normal volunteer study and focused the value of these
tests on resistance-based, rather than reflux-based, param-
eters. The results obtained under the SUBR  condition
were considered particularly relevant since this case had a
longer cycle period (4 s versus 2 s) and, thus, was more
'quasi-steady'. Reflux, on the other hand, was observed
with both standing positions. However, the STAF simula-
tion did not allow as much reflux as the STBR condition
because of the higher frequency of the roller pump, which
acted as an effective valve and, thus, limited reflux. For
example, in the 'No Device' case, only 24.6% reflux was
observed under the STAF condition as compared to 205%
reflux in the STBR condition. Therefore, it was concluded
that test valves would not be exposed to reversing flows
under the STAF condition, which are large enough to dis-
tinguish between valve designs. The finding that %Ref
exceeded 100% and η exceeded -300% for STBR under-
scores the fact that back flow in the veins is not primarily
dependent upon the amount of forward flow per se but
rather, upon the backpressure acting on the valve. In other
words, a successful vein valve should first be able to pre-
vent backflow of blood from the entire proximal vein and
then, secondly, it should limit backflow beyond the point
where the net forward flow is less than that required to
maintain normal flow through the vessel.
Repeatability testing showed that, for a representative
device, there were some statistically different values in the
measured and computed variables between runs. These
differences existed for all parameters under simulated
'breathing' conditions (i.e. SUBR and STBR) but only 2 of
7 parameters (ΔP and R) under simulated 'ankle flexion'
conditions (i.e. SUAF and STAF). While these differences
will limit the test system's ability to distinguish one valve
design from another to some extent, most of the variabil-
ity is relatively small compared to the 'No Device' case
[Tables 2 and 3], and thus, should accurately reflect the
improvement expected compared to a completely defec-
tive valve.
VR
Table 4: 1:1 Pulsatile Flow Results for Repeat Measurements in Supine Position.
Test Condition Test Run ΔP1 (mmHg) R1 (mmHg*min/L) EOA (cm2)
SUBR 1st 1.33 ± 0.0012 2.23 ± 0.0338 1.12 ± 0.0166
2nd 1.41 ± 0.0221* 2.29 ± 0.0379* 1.16 ± 0.015*
Change 0.08 0.06 0.04
SUAF 1st 1.84 ± 0.151 1.37 ± 0.110 1.09 ± 0.0111
2nd 2.33 ± 0.0926* 1.73 ± 0.0889* 1.08 ± 0.0215
Change 0.49 0.36 0.01
1 Relative to 'No Device' value
* p < 0.05 vs. 1st Test Run
Table 3: 1:1 Pulsatile Flow Results for Prototype vs. 'No Device' in Standing Position.
Test Condition Device (cm3) %Ref (%) REL (mJ) η (%)
STBR None 59.6 ± 0.830 205 ± 5.37 283 ± 7.93 -319 ± 22.1
Prototype 5.83 ± 0.688 18.1 ± 2.12 2.73 ± 0.654 36.7 ± 0.785
STAF None 7.35 ± 0.28 24.6 ± 0.859 4.30 ± 0.333 93.9 ± 0.429
Prototype 2.21 ± 0.978 7.10 ± 3.27 0.451 ± 0.411 99.4 ± 0.562
VRBioMedical Engineering OnLine 2007, 6:29 http://www.biomedical-engineering-online.com/content/6/1/29
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Finally, it is important to note that neither of these in vitro
test systems used collapsible tubing in the test section as
some earlier studies had done (15–17). While this feature
would clearly have altered the results obtained, and espe-
cially the reflux flow data, it was felt that during the initial
design testing phase, it was best to use a system which
would evaluate the capabilities of the various devices
themselves independent of other factors. Based on those
results, then, appropriate improvements could be incor-
porated and/or final selections made between competing
designs. Once optimized, the final design could then be
re-tested with the addition of collapsible tubing to deter-
mine the physiologic response of the prototypic valve +
vein combination.
Conclusion
From these results, it was concluded that the initial test
device produced only a small increases in ΔP  (<0.15
mmHg) and R  (<0.25 mmHg*min/L) and a small
decrease in EOA (<8%) relative to 'No Device'. Further-
more, it allowed <2% of   and <6% of the REL
observed with 'No Device'. Thus, the overall test systems
and procedures used proved quite valuable in carrying out
this phase of the design process. Further studies are now
planned to evaluate biocompatibility concerns such as
thrombogenicity and intimal hyperplasia of these devices
in vivo.
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